Venlafaxine besylate
US6717015B2 · kind B2 · utility
9Cited by
11References
49Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 27, 2003 |
| Grant date | Apr 6, 2004 |
| Priority date | — |
| Expiry date | Mar 27, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2601/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Venlafaxine besylate compounds provide certain advantages over venlafaxine hydrochloride and are useful in forming pharmaceutical compositions and n treating venlafaxine-treatable diseases and conditions. Venlafaxine besylate can be easily formulated into an extended release dosage form including a hydrogel tablet as well as other matrix-based tablet compositions. A preferred tablet making process involves hot melt granulation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.